Latest Breaking News On - Ovid therapeutics company profile - Page 1 : comparemela.com

HC Wainwright Reaffirms Buy Rating for Ovid Therapeutics (NASDAQ:OVID)

HC Wainwright reaffirmed their buy rating on shares of Ovid Therapeutics (NASDAQ:OVID – Free Report) in a research note issued to investors on Thursday morning, Benzinga reports. HC Wainwright currently has a $9.00 target price on the stock. Other analysts also recently issued reports about the stock. Wedbush began coverage on shares of Ovid Therapeutics […]

United statesJeremym levinSg americas securitiesJump financialOvid therapeutics company profileOvid therapeutics incSecurities exchange commissionChina universal asset management coWealth managementOvid therapeuticsFree reportModerate buyGet free reportExchange commissionUniversal asset managementTherapeutics inc

Brokerages Set Ovid Therapeutics Inc (NASDAQ:OVID) PT at $8 08

Brokerages Set Ovid Therapeutics Inc (NASDAQ:OVID) PT at $8 08
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United statesJeremym levinOvid therapeutics company profileJump financialOvid therapeutics incSg americas securitiesSecurities exchange commissionWealth managementOvid therapeuticsGet free reportExchange commissionPoint capitalGet freeTherapeutics incOvid therapeutics daily

Ovid Therapeutics (NASDAQ:OVID) PT Lowered to $3 50 at Citigroup

Ovid Therapeutics (NASDAQ:OVID) PT Lowered to $3 50 at Citigroup
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United statesJeremym levinConnor clark lunn investment management ltdJump financialOvid therapeutics company profileChina universal asset management coSg americas securitiesOvid therapeutics incOvid therapeuticsGet free reportTherapeutics trading downLunn investment managementChina universal asset managementTherapeutics incOvid therapeutics daily

Ovid Therapeutics (NASDAQ:OVID) Earns Buy Rating from Analysts at B Riley

Ovid Therapeutics (NASDAQ:OVID) Earns Buy Rating from Analysts at B Riley
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

United statesJeremym levinOvid therapeutics company profileWealth managementSg americas securitiesOvid therapeutics incJump financialOvid therapeuticsFree reportTherapeutics trading downGet free reportPoint capitalTherapeutics incOvid therapeutics daily

HC Wainwright Initiates Coverage on Ovid Therapeutics (NASDAQ:OVID)

HC Wainwright began coverage on shares of Ovid Therapeutics (NASDAQ:OVID – Free Report) in a research note issued to investors on Monday, MarketBeat reports. The firm issued a buy rating and a $9.00 price target on the stock. HC Wainwright also issued estimates for Ovid Therapeutics’ Q1 2024 earnings at ($0.22) EPS, Q2 2024 earnings […]

United statesJeremym levinSg americas securitiesJump financialOvid therapeutics company profileOvid therapeutics incChina universal asset management coOvid therapeuticsFree reportGet free reportUniversal asset managementFinancial marketsTherapeutics incOvid therapeutics dailyNasdaq ovidInitiated coverage